Sakar Healthcare Intrinsic Value
Sakar Healthcare intrinsic value. Sakar Healthcare (SAKAR) median intrinsic value is ₹306.53 from 9 valuation models (range ₹295–₹503), vs current price ₹1006.80 — -69.6% downside (Trading Above Calculated Value), margin of safety -100.0%. Read Sakar Healthcare dividend policy for the complete payout history and dividend yield track record.
SAKAR Valuation Methods Summary — DCF, Graham Number & P/E
Sakar Healthcare intrinsic value across 9 models vs current price ₹1006.80 — upside/downside and value range per method. For current market price and key ratios, visit Sakar Healthcare share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹436.48 | ₹349.18 - ₹523.78 | -56.6% | EPS: ₹19.84, Sector P/E: 22x |
| Book Value Method | asset | ₹295.45 | ₹265.90 - ₹325.00 | -70.7% | Book Value/Share: ₹147.73, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹302.04 | ₹271.84 - ₹332.24 | -70.0% | Revenue/Share: ₹129.09, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹472.73 | ₹425.46 - ₹520.00 | -53.0% | EBITDA: ₹104.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹402.72 | ₹322.18 - ₹483.26 | -60.0% | CF Growth: 8.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹302.04 | ₹271.84 - ₹332.24 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹306.53 | ₹275.88 - ₹337.18 | -69.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹503.40 | ₹453.06 - ₹553.74 | -50.0% | ROE: 13.5%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹302.04 | ₹271.84 - ₹332.24 | -70.0% | EPS: ₹19.84, BVPS: ₹147.73 |
SAKAR Intrinsic Value vs Market Price — All Valuation Models
Sakar Healthcare fair value range ₹295–₹503 vs current market price ₹1006.80 across 9 valuation models. Compare with SAKAR stock valuation models to assess whether the stock is under or overvalued.
SAKAR Intrinsic Value Analysis — Undervalued or Overvalued?
Sakar Healthcare median intrinsic value ₹306.53, current price ₹1006.80 — Trading Above Calculated Value by 69.6%, margin of safety -100.0%.
What is the intrinsic value of SAKAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sakar Healthcare (SAKAR) is ₹306.53 (median value). With the current market price of ₹1006.80, this represents a -69.6% variance from our estimated fair value.
The valuation range spans from ₹295.45 to ₹503.40, indicating ₹295.45 - ₹503.40.
Is SAKAR undervalued or overvalued?
Based on our multi-method analysis, Sakar Healthcare (SAKAR) appears to be trading above calculated value by approximately 69.6%.
SAKAR Financial Health — Key Ratios vs Industry Benchmarks
Sakar Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.5% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 37.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.59x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SAKAR Cash Flow Quality — Operating & Free Cash Flow
Sakar Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹49 Cr | ₹35 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹34 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹25 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹33 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹36 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |